Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 557-562

  Minamimoto, Ryogo ^a   Hancock, Steven ^b   Schneider, Bernadette ^a   Chin, Frederick T ^a   Jamali, Mehran ^a   Loening, Andreas ^b   Vasanawala, Shreyas ^b   Gambhir, Sanjiv Sam ^a   Iagaru, Andrei ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

68Ga; PET CT; PET MRI; Prostate cancer; PSMA; RM2

Indexed keywords

GLUTAMIC ACID NH CO NH LYSINE (AHX) HBED CC GA 68; PROSTATE SPECIFIC ANTIGEN; TETRAXETAN 4 AMINO 1 CARBOXYMETHYL PIPERIDINE DELTA PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYLGLYCYLHISTIDYLSTALEUCINAMIDE GA 68; TRACER; UNCLASSIFIED DRUG; (68GA)GLU-UREA-LYS(AHX)-HBED-CC; BAY 86-7548; OLIGOPEPTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

AGED; ARTICLE; BILIARY CLEARANCE; CANCER RECURRENCE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; ISOTOPE LABELING; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAAORTIC LYMPH NODE; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIOACTIVITY; RENAL CLEARANCE; VERY ELDERLY; CLINICAL TRIAL; IMAGE PROCESSING; LYMPH NODE; METABOLISM; PROCEDURES; PROSTATE TUMOR; SALIVARY GLAND; SCINTISCANNING; SEMINAL VESICLE; SMALL INTESTINE; TISSUE DISTRIBUTION; TUMOR RECURRENCE; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTESTINE, SMALL; LYMPH NODES; MALE; NEOPLASM RECURRENCE, LOCAL; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SALIVARY GLANDS; SEMINAL VESICLES; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84963961482     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.168393     Document Type: Article

References (30)

1. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999; 17:168-172.
2. Hanlon AL, Moore DF, Hanks GE. Modeling postradiation prostate specific antigen level kinetics: predictors of rising postnadir slope suggest cure in men who remain biochemically free of prostate carcinoma. Cancer. 1998;83: 130-134.
3. Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: role of imaging. AJR. 2009;192:1455-1470.
4. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med. 2003;44: 549-555.
5. 18F]fluorodeoxyglucosepositron emission tomography. J Urol. 2003;169:1337-1340.
6. 11C-acetate PET in the early evaluation of prostate cancer recurrence. Eur J Nucl Med Mol Imaging. 2007;34: 185-196.
7. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol. 2006;24:2513-2519.
8. 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. J Nucl Med. 2013;54:833-840.
9. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/ computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA , 5 ng/ml? Mol Imaging Biol. 2006;8:43-48.
10. 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (,1 ng/mL) after radical prostatectomy. BJU Int. 2007;99:1415-1420.
11. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637-640.
12. Eder M, Eisenhut M, Babich J, Haberkorn U. PSMA as a target for radiolabelled small molecules. Eur J Nucl Med Mol Imaging. 2013;40:819-823.
13. Zechmann C, Afshar-Oromieh A, Armor T, et al. Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging. 2014;41:1280-1292.
14. 68Ga-and 177Lu-Labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-ofconcept human studies. J Nucl Med. 2015;56:1169-1176.
15. Ahmadzadehfar H, Rahbar K, Kurpig S, et al. Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5:114.
16. 68Ga]galliumlabelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J NuclMedMol Imaging. 2013;40:486-495.
17. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60:1-42.
18. Reubi JC,Wenger S, Schmuckli-Maurer J, Schaer J-C, GuggerM. Bombesin receptor subtypes in human cancers: detection with the universal radioligand 125I-[d-TYR6, b-ALA11, PHE13, NLE14] bombesin(6-14). Clin Cancer Res. 2002;8:1139-1146.
19. Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42:295-303.
20. Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59:1152-1159.
21. 68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014;7:779-796.
22. 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. Clin Nucl Med. 2015;40:1-8.
23. Eder M, Schafer M, Bauder-Wust U, Haberkorn U, Eisenhut M, Kopka K. Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate. 2014;74:659-668.
24. 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54:867-872.
25. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197-209.
26. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668-674.
27. 68Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. J Nucl Med. 2015;56:1185-1190.
28. 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41:11-20.
29. 68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19:5434-5443.
30. de Visser M, van Weerden WM, de Ridder CM, et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med. 2007;48:88-93.